Phase 2 study of bevacizumab beyond progression disease for glioblastoma treated with key therapeutics.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 20 Feb 2017
At a glance
- Drugs Bevacizumab (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Therapeutic Use
- Acronyms BIOMARK
- Sponsors EPS Corporation
- 16 Feb 2017 Status changed from recruiting to active, no longer recruiting.
- 02 Apr 2015 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network record.
- 03 Mar 2015 New trial record